HistoSpring Wins U.S. Patent for ER-Mediated DNA Damage Method

HistoSpring said June 24, 2026, that the U.S. Patent and Trademark Office issued a patent for methods that predict estrogen receptor-mediated DNA damage. The technology could help researchers assess breast cancer risk, screen endocrine-disrupting chemicals and guide ER+ breast cancer therapy selection.

Why it matters: - The patent adds a new tool for evaluating how estrogenic compounds may drive genomic instability in breast cells. - The method could improve breast cancer risk assessment by identifying chemicals linked to DNA damage through estrogen receptor signaling. - The technology may also support screening of endocrine-disrupting chemicals and research in toxicology and drug development. - The patent can help guide therapy selection for ER+ breast cancers.

What happened: - HistoSpring announced the issuance of U.S. Patent No. 12,590,950 B2 on June 24, 2026. - The patent is titled “Methods for Predicting ER-Mediated DNA Damage.” - The invention covers methods for identifying estrogenic compounds and endocrine-disrupting chemicals that induce estrogen receptor-mediated DNA damage and genomic instability in breast cells. - HistoSpring said the patent expands its portfolio supporting cancer research and translational discovery.

The details: - The patented approach measures biomarkers associated with DNA damage, including γH2AX intensity and R-loop formation, after exposure to estrogenic compounds. - Research supporting the patent showed that estradiol, benzophenone-3 (BP3) and propyl paraben (PP) can induce ER-mediated genomic instability in breast epithelial cells. - HistoSpring said the work provides a platform for breast cancer risk assessment, environmental chemical screening, endocrine disruptor evaluation, and toxicology and drug development research. - HistoSpring is a biomedical company focused on histology services, digital pathology, biomarker analysis and research resources for oncology and translational discovery. - The company says its platform combines histology expertise, advanced imaging, automated staining and HALO® AI-driven tissue analysis. - HistoSpring also provides wet lab resources and access to cell and tissue models. - The company lists its website as more information and provides direct contact at info@histospring.com and 413-794-0523. - HistoSpring also shared a LinkedIn page at the company's LinkedIn page.

Between the lines: - The patent suggests HistoSpring is positioning its research tools at the intersection of chemical safety, cancer biology and precision medicine. - The focus on estrogen receptor signaling matters because ER pathways are central to a subset of breast cancers and to how some environmental compounds interact with cells. - The biomarker-based method may offer a more molecular way to study risk than broader toxicity screening alone.

What's next: - HistoSpring said the technology could support future discoveries in breast cancer biology and prevention research. - Researchers may use the patent-backed method to evaluate additional estrogenic compounds and endocrine disruptors. - The company may apply the platform across cancer risk, toxicology and therapeutic development studies.

The bottom line: - HistoSpring’s new patent gives the company a protected method for measuring ER-mediated DNA damage, a capability that could sharpen chemical screening and breast cancer research.